Fisher and Paykel’s
(ASX:FPH) Optiflow nasal high flow therapy has shown significant benefits for children in new Australian research.
In what has been the world’s largest randomised controlled trial in nasal high flow therapy it shows that it can significantly lower rates of escalation of care for infants with bronchiolitis.
The research was carried out by a team at Lady Cilento Children’s hospital in Brisbane.
The study will help drive change in the use of the Optiflow nasal high flow therapy.
Shares in Fisher and Paykel’s
(ASX:FPH) are trading 0.57 per cent lower to $12.22
